IV Chelation therapy is the process of administering chelating agents, EDTA and/or DMPS, directly into the veins to remove heavy metals from the body. This procedure has been safely used since the 1940’s as a primary treatment for lead poisoning. Today we use chelation for the removal of numerous toxic metals like Mercury, Aluminum, Cadmium, and Arsenic.  Chelation works by binding to the heavy metals in the blood so they can be excreted from the body mainly through the urine. Chelation therapy can also be used to treat atherosclerosis and other chronic degenerative diseases.  CaEDTA (Calcium Ethylenediaminetetraacetic acid) is most commonly used in cases of heavy metal toxicity while MgEDTA (Magnesium Ethylenediaminetetraacetic acid) is used for treating atherosclerosis. Calcium is a component of the atherosclerotic plaque in coronary heart disease, which ultimately  leads to heart attacks. The chelation or binding of calcium by MgEDTA can potentially  result in the removal of plaque and calcium deposits from arteries and veins. There is currently a joint venture study going on Chelation between the National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute (NHLBI). This study is called Trial to Assess Chelation Therapy (TACT). It is a 5 year study involving over 2,300 patients (Administration, 2013). Overall the study did find a reduction in adverse cardiovascular outcomes in patients who were administered the IV Chelation therapy (GA et al., 2013).

To find out if IV Chelation therapy is right for you, call or text Dr. Sara for an appointment at (310) 849-2244.




Administration, U. S. F. a. D. (2013, August 2013). Trial to Assess Chelation Therapy (TACT)  Retrieved December 15, 2013, from http://www.clinicaltrials.gov/ct2/show/results/NCT00044213?term=chelation&rank=4&sect=X63015#outcome1

GA, L., C, G., R, B., DB, M., T, R., RL, N., . . . Investigators, T. (2013). Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA, 309(12), 1241-1250.